Q4 2024 Earnings Call Transcript February 26, 2025 Theravance Biopharma, Inc. misses on earnings expectations. Reported EPS is $-0.31 EPS, expectations were $0.26. Operator: Ladies and gentlemen, good ...

Elaine Varelas advises on how preparing a presentation for a C-suite interview can be an effective way to distinguish yourself from other candidates. The post I want to stand out as a candidate for a ...

Brookfield's plan value for wealth solutions is $30 billion by 2026 and $58 billion by 2029, driven by insurance assets ...

Welcome to the Seer fourth quarter and full year 2024 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the ...

Full Year Results Earnings Conference Call February 26, 2025 6:00 AM ETCompany ParticipantsMathilde Rodié – Head of ...

Travelzoo (NASDAQ: TZOO) Q4 2024 Earnings Call Transcript February 25, 2025 ...

Doug Gentilcore; DANYELZA Business Unit Head; Y-mAbs Therapeutics Inc Natalie Tucker; Senior Vice President and Radiopharmaceutical Business Unit Head; Y-mAbs Therapeutics Inc Thank you, operator, and ...

Operator: Good day, and thank you for standing by. Welcome to the Q2 2025 Brady Corporation earnings conference call. At this ...

Ideal Power Inc. (Nasdaq: IPWR) ("Ideal Power," the "Company," "we," "us" or "our"), developer and innovative provider ...

Revuforj® (revumenib) net product revenue in initial five weeks of launch –– Launched Niktimvo™ (axatilimab-csfr) in the U.S.

Audited results confirm full-year revenue of DKK 5,716 million and EBITDA of DKK 1,603 million. <li /> Two new early-stage pipeline pro ...

At this time, I would like to welcome everyone to the IFF fourth-quarter and full year 2024 earnings conference call. (Operator Instructions) I would like to introduce Michael Bender, Head of Investor ...